Catalent to Present Bioavailabity Solutions & Drug Delivery Toolkit at InformEx
Somerset, N.J. – February 2, 2015 — Catalent Pharma Solutions (Booth 1611), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, will deliver a presentation on Catalent’s recent acquisition of market leading particle size engineering company, Micron Technologies, at the InformEx tradeshow, to be held at the Morial Convention Center, New Orleans, LA, between February 3rd and 5th, 2015.
The showcase, to be held at 9.20 am on Tuesday February 3rd, in Room 222, will be given by Michael McDougal, Director, Business Development at Micron Technologies.
Particle size engineering techniques, such as micronization, enable effective and cost-efficient particle reduction of crystalline formulations, which can aid solubility of compounds and improve the uniform distribution of API within formulations. Particle size is inherently linked to dissolution and absorption rates of APIs within the body and both are fundamental to the performance of a drug product.
Catalent acquired Micron Technologies in November 2014, expanding the company’s bioavailability and solubility services offer. With the addition of particle size engineering expertise and experience, Catalent can now help clients at the earliest stages of the drug development process and provide end-to-end solutions to accelerate programs to clinic and market with an unrivalled set of bioavailability solutions in its toolkit.
To arrange a meeting with Catalent at InformEx,
contact Richard Kerns at NEPR: richard@nepr.eu
For further information on InformEx visit www.informex.com
Media Contacts:
Chris Halling
+44 (0)7580 041073
chris.halling@catalent.com
Richard Kerns
+44 (0) 161 728 5880
richard@nepr.eu
About Catalent
Catalent Pharma Solutions is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,000 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and in fiscal 2014 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit www.catalent.com